Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7722093rdf:typepubmed:Citationlld:pubmed
pubmed-article:7722093lifeskim:mentionsumls-concept:C0038172lld:lifeskim
pubmed-article:7722093lifeskim:mentionsumls-concept:C0037278lld:lifeskim
pubmed-article:7722093lifeskim:mentionsumls-concept:C0949665lld:lifeskim
pubmed-article:7722093lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:7722093lifeskim:mentionsumls-concept:C0205409lld:lifeskim
pubmed-article:7722093lifeskim:mentionsumls-concept:C0332325lld:lifeskim
pubmed-article:7722093pubmed:issue2lld:pubmed
pubmed-article:7722093pubmed:dateCreated1995-5-23lld:pubmed
pubmed-article:7722093pubmed:abstractTextThe in vitro susceptibility of Staphylococcus aureus to eight fluoroquinolones, norfloxacin, ofloxacin, enoxacin, ciprofloxacin, lomefloxacin, tosufloxacin, sparfloxacin, and nadifloxacin was established by agar dilution tests, 71 isolates of methicillin-susceptible (MSSA) and 74 isolates of -resistant S. aureus (MRSA) isolated from skin infections. Among all of the fluoroquinolones, nadifloxacin exhibited the lowest MIC for both MSSA and MRSA. In addition, there were no resistant S. aureus, neither MSSA and MRSA, to nadifloxacin. With the exception of nadifloxacin, the incidence of MRSA resistant to fluoroquinolones has gradually increased in recent years. Over half of the MRSA strains were resistant to norfloxacin, ofloxacin, enoxacin, ciprofloxacin, and lomefloxacin.lld:pubmed
pubmed-article:7722093pubmed:languageenglld:pubmed
pubmed-article:7722093pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7722093pubmed:citationSubsetIMlld:pubmed
pubmed-article:7722093pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7722093pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7722093pubmed:statusMEDLINElld:pubmed
pubmed-article:7722093pubmed:monthFeblld:pubmed
pubmed-article:7722093pubmed:issn0385-2407lld:pubmed
pubmed-article:7722093pubmed:authorpubmed-author:AsadaYYlld:pubmed
pubmed-article:7722093pubmed:authorpubmed-author:FujitaMMlld:pubmed
pubmed-article:7722093pubmed:authorpubmed-author:KawaiSSlld:pubmed
pubmed-article:7722093pubmed:authorpubmed-author:KawabataSSlld:pubmed
pubmed-article:7722093pubmed:authorpubmed-author:AkamatsuHHlld:pubmed
pubmed-article:7722093pubmed:authorpubmed-author:NamuraSSlld:pubmed
pubmed-article:7722093pubmed:authorpubmed-author:NishijimaSSlld:pubmed
pubmed-article:7722093pubmed:issnTypePrintlld:pubmed
pubmed-article:7722093pubmed:volume22lld:pubmed
pubmed-article:7722093pubmed:ownerNLMlld:pubmed
pubmed-article:7722093pubmed:authorsCompleteYlld:pubmed
pubmed-article:7722093pubmed:pagination153-5lld:pubmed
pubmed-article:7722093pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:7722093pubmed:meshHeadingpubmed-meshheading:7722093-...lld:pubmed
pubmed-article:7722093pubmed:meshHeadingpubmed-meshheading:7722093-...lld:pubmed
pubmed-article:7722093pubmed:meshHeadingpubmed-meshheading:7722093-...lld:pubmed
pubmed-article:7722093pubmed:meshHeadingpubmed-meshheading:7722093-...lld:pubmed
pubmed-article:7722093pubmed:meshHeadingpubmed-meshheading:7722093-...lld:pubmed
pubmed-article:7722093pubmed:meshHeadingpubmed-meshheading:7722093-...lld:pubmed
pubmed-article:7722093pubmed:meshHeadingpubmed-meshheading:7722093-...lld:pubmed
pubmed-article:7722093pubmed:year1995lld:pubmed
pubmed-article:7722093pubmed:articleTitleActivity of eight fluoroquinolones against both methicillin-susceptible and -resistant Staphylococcus aureus isolated from skin infections.lld:pubmed
pubmed-article:7722093pubmed:affiliationDivision of Dermatology, Kansai Medical University, Kori Branch Hospital, Osaka, Japan.lld:pubmed
pubmed-article:7722093pubmed:publicationTypeJournal Articlelld:pubmed